AWAWU E. IGBINADOLOR
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Adolescent Medicine
- Where
- Monroe, NC
- NPI
- 1386658128
- Received
- $703,113 in 135 records, 2019 to 2025 ($6,981 general, $696,132 research)
- As principal investigator
- $22,136,125 of research payments to others in 2,094 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 1 | $15 |
| 2024 | General payment | 14 | $3,264 |
| 2024 | Research payment | 2 | $24,803 |
| 2023 | General payment | 8 | $1,376 |
| 2023 | Research payment | 12 | $5,441 |
| 2022 | General payment | 38 | $635 |
| 2022 | Research payment | 2 | $99,385 |
| 2021 | General payment | 23 | $613 |
| 2021 | Research payment | 3 | $421,014 |
| 2020 | General payment | 11 | $250 |
| 2020 | Research payment | 2 | $145,488 |
| 2019 | General payment | 19 | $825 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 12 | $694,883 | 2020–2024 |
| Alnylam Pharmaceuticals Inc. | 7 | $2,070 | 2024 |
| Novartis Pharmaceuticals Corporation | 7 | $1,273 | 2019–2024 |
| SANOFI PASTEUR INC. | 9 | $1,249 | 2023 |
| ModernaTX, Inc. | 5 | $1,117 | 2023 |
| Novo Nordisk Inc | 27 | $537 | 2019–2022 |
| AstraZeneca Pharmaceuticals LP | 17 | $284 | 2019–2024 |
| MERZ NORTH AMERICA, INC. | 2 | $278 | 2019 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $200 | 2021–2022 |
| Abbott Laboratories | 7 | $132 | 2021–2022 |
| ViiV Healthcare Company | 1 | $125 | 2023 |
| Amgen Inc. | 1 | $125 | 2024 |
| Horizon Therapeutics plc | 1 | $116 | 2023 |
| Janssen Pharmaceuticals, Inc | 1 | $107 | 2019 |
| Gilead Sciences, Inc. | 1 | $104 | 2019 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $103 | 2020–2021 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $89 | 2019–2022 |
| GlaxoSmithKline, LLC. | 4 | $65 | 2020–2022 |
| Lilly USA, LLC | 4 | $64 | 2021–2022 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $59 | 2019–2021 |
| ABBVIE INC. | 2 | $43 | 2022 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 | 2021 |
| SANOFI-AVENTIS U.S. LLC | 1 | $16 | 2020 |
| Exact Sciences Corporation | 1 | $15 | 2025 |
| Merck Sharp & Dohme LLC | 1 | $14 | 2022 |
| ALK-Abello, Inc | 1 | $13 | 2020 |
| PFIZER INC. | 1 | $5 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 21 | $696,132 |
| Food and Beverage | 100 | $3,642 |
| Travel and Lodging | 10 | $3,302 |
| Education | 4 | $36 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-04-28 | Exact Sciences Corporation | $15 | Food and Beverage | In-kind items and services | The Cologuard Plus Collection Kit Device, Oncology | 2025 | |
| 2024-09-23 | Eli Lilly and Company | $24,187 | Research payment | Cash or cash equivalent | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH | 2024 | |
| 2024-09-23 | Eli Lilly and Company | $616 | Research payment | Cash or cash equivalent | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET | 2024 | |
| 2024-09-22 | Novartis Pharmaceuticals Corporation | $526 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-09-22 | Novartis Pharmaceuticals Corporation | $235 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-09-22 | Novartis Pharmaceuticals Corporation | $111 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-22 | Novartis Pharmaceuticals Corporation | $9 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-09-21 | Novartis Pharmaceuticals Corporation | $172 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-05 | Alnylam Pharmaceuticals Inc. | $371 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-04-05 | Alnylam Pharmaceuticals Inc. | $151 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-04-04 | Alnylam Pharmaceuticals Inc. | $125 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-04 | Alnylam Pharmaceuticals Inc. | $105 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-04 | Alnylam Pharmaceuticals Inc. | $82 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-03 | Alnylam Pharmaceuticals Inc. | $1,081 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-04-03 | Alnylam Pharmaceuticals Inc. | $151 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-01-22 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-01-20 | Amgen Inc. | $125 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, Inflammation/Rare Disease | 2024 | |
| 2023-10-06 | SANOFI PASTEUR INC. | $72 | Research payment | In-kind items and services | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine | 2023 | |
| 2023-10-06 | SANOFI PASTEUR INC. | $55 | Research payment | In-kind items and services | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine | 2023 | |
| 2023-10-06 | SANOFI PASTEUR INC. | $30 | Research payment | In-kind items and services | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine | 2023 | |
| 2023-10-05 | SANOFI PASTEUR INC. | $536 | Research payment | In-kind items and services | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine | 2023 | |
| 2023-10-05 | SANOFI PASTEUR INC. | $269 | Research payment | In-kind items and services | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine | 2023 | |
| 2023-10-05 | SANOFI PASTEUR INC. | $136 | Research payment | In-kind items and services | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine | 2023 | |
| 2023-10-05 | SANOFI PASTEUR INC. | $68 | Research payment | In-kind items and services | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine | 2023 | |
| 2023-10-05 | SANOFI PASTEUR INC. | $52 | Research payment | In-kind items and services | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine | 2023 | |
| 2023-10-05 | SANOFI PASTEUR INC. | $30 | Research payment | In-kind items and services | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine | 2023 | |
| 2023-08-17 | ModernaTX, Inc. | $392 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-08-17 | ModernaTX, Inc. | $293 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-08-17 | ModernaTX, Inc. | $206 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-08-17 | ModernaTX, Inc. | $174 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-08-17 | ModernaTX, Inc. | $50 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-06-27 | Eli Lilly and Company | $223 | Research payment | In-kind items and services | A PHASE 3 12 MONTH OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2023 | |
| 2023-06-27 | Eli Lilly and Company | $201 | Research payment | In-kind items and services | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATM | 2023 | |
| 2023-05-20 | Horizon Therapeutics plc | $116 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, KRYSTEXXA | 2023 | |
| 2023-03-30 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-02-18 | ViiV Healthcare Company | $125 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-01-10 | Eli Lilly and Company | $3,767 | Research payment | In-kind items and services | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 | |
| 2022-12-05 | Merck Sharp & Dohme LLC | $14 | Food and Beverage | In-kind items and services | PIFELTRO Drug, INFECTIOUS DISEASE | 2022 | |
| 2022-11-14 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2022 | |
| 2022-11-07 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2022 | |
| 2022-10-14 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-10-11 | Abbott Laboratories | $15 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2022 | |
| 2022-09-29 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-09-15 | Bayer Healthcare Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-09-03 | Novo Nordisk Inc | $10 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-08-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-08-18 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-08-15 | Bayer Healthcare Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-08-04 | Abbott Laboratories | $21 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2022 | |
| 2022-07-27 | Abbott Laboratories | $19 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2022 | |
| 2022-07-21 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-07-21 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-07-20 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2022 | |
| 2022-07-13 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-06-30 | Eli Lilly and Company | $71,962 | Research payment | In-kind items and services | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A W | 2022 | |
| 2022-06-23 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2022-06-06 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-06-01 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-06-01 | Novo Nordisk Inc | $8 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-05-16 | Novo Nordisk Inc | $7 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-05-09 | Bayer Healthcare Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-04-27 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2022 | |
| 2022-04-14 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-04-11 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-04-08 | Eli Lilly and Company | $27,423 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-04-01 | Novo Nordisk Inc | $5 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-04-01 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-03-21 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-03-17 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-03-10 | Novo Nordisk Inc | $6 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-03-09 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-03-07 | Bayer Healthcare Pharmaceuticals Inc. | $18 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-02-16 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-02-07 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2022 | |
| 2022-02-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-01-24 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2022 | |
| 2022-01-12 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2021-12-13 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2021 | |
| 2021-12-13 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2021 | |
| 2021-10-06 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2021 | |
| 2021-09-29 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $83 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2021 | |
| 2021-09-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-09-09 | Abbott Laboratories | $12 | Food and Beverage | In-kind items and services | FreeStyle Libre 2 Device, Diabetes Care | 2021 | |
| 2021-09-08 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2021 | |
| 2021-09-02 | Novo Nordisk Inc | $113 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-08-25 | Takeda Pharmaceuticals U.S.A., Inc. | $20 | Food and Beverage | In-kind items and services | MOTEGRITY Drug, INTERNAL MEDICINE | 2021 | |
| 2021-08-18 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-08-16 | Bayer Healthcare Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2021 | |
| 2021-08-16 | Abbott Laboratories | $22 | Food and Beverage | In-kind items and services | FreeStyle Libre 2 Device, Diabetes Care | 2021 | |
| 2021-08-12 | Teva Pharmaceuticals USA, Inc. | $16 | Food and Beverage | In-kind items and services | AirDuo Digihaler Drug, Respiratory | 2021 | |
| 2021-08-12 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | PREMARIN Drug, WOMENS HEALTH | 2021 | |
| 2021-07-28 | AstraZeneca Pharmaceuticals LP | $11 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-07-20 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | FreeStyle Libre 2 Device, Diabetes Care | 2021 | |
| 2021-06-30 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2021 | |
| 2021-06-24 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-05-13 | Novo Nordisk Inc | $101 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-05-03 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-04-08 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-03-03 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2021 | |
| 2021-02-24 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | ANORO ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-01-11 | Eli Lilly and Company | $22,722 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATIO | 2021 | |
| 2021-01-05 | Eli Lilly and Company | $194,141 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY383 | 2021 | |
| 2021-01-04 | Eli Lilly and Company | $204,151 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY383 | 2021 | |
| 2020-12-15 | Eli Lilly and Company | $133,209 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY383 | 2020 | |
| 2020-10-28 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | BREZTRI AEROSPHERE Drug, Respiratory | 2020 | |
| 2020-10-15 | Eli Lilly and Company | $12,279 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY383 | 2020 | |
| 2020-09-14 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-07-31 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-07-23 | SANOFI-AVENTIS U.S. LLC | $16 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrinology | 2020 | |
| 2020-07-15 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-06-10 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2020 | |
| 2020-06-04 | ALK-Abello, Inc | $13 | Food and Beverage | In-kind items and services | Timothy Grass (phleum pratense) Biological | 2020 | |
| 2020-03-11 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-02-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20 | Food and Beverage | In-kind items and services | XIFAXAN Drug, GASTROENTEROLOGY | 2020 | |
| 2020-02-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2020 | |
| 2020-01-31 | Novartis Pharmaceuticals Corporation | $97 | Food and Beverage | In-kind items and services | 2020 | ||
| 2019-09-05 | Novartis Pharmaceuticals Corporation | $121 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Education | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-07-26 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-07-24 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2019 | |
| 2019-06-19 | Takeda Pharmaceuticals U.S.A., Inc. | $15 | Food and Beverage | In-kind items and services | Motegrity Drug, Lower GI | 2019 | |
| 2019-05-22 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2019 | |
| 2019-05-18 | Janssen Pharmaceuticals, Inc | $107 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-05-10 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-05-09 | Takeda Pharmaceuticals U.S.A., Inc. | $1 | Education | In-kind items and services | Amitiza Drug, Lower GI | 2019 | |
| 2019-04-27 | Gilead Sciences, Inc. | $104 | Food and Beverage | In-kind items and services | Truvada Drug, HIV | 2019 | |
| 2019-04-05 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-03-29 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2019 | |
| 2019-02-22 | AstraZeneca Pharmaceuticals LP | $12 | Education (2 payments) | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-02-08 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-02-01 | Takeda Pharmaceuticals U.S.A., Inc. | $13 | Food and Beverage | In-kind items and services | Trintellix Drug, Central Nervous System (CNS) | 2019 | |
| 2019-01-31 | Takeda Pharmaceuticals U.S.A., Inc. | $7 | Education | In-kind items and services | Trintellix Drug, Central Nervous System (CNS) | 2019 | |
| 2019-01-29 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage (4 payments) | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-01-12 | MERZ NORTH AMERICA, INC. | $151 | Food and Beverage | Cash or cash equivalent | XEOMIN Biological, DERMATOLOGY | 2019 | |
| 2019-01-12 | MERZ NORTH AMERICA, INC. | $126 | Food and Beverage | Cash or cash equivalent | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | Monroe Biomedical Research | $19,416 | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupirav | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | Monroe Biomedical Research | $274 | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupirav | 2025 |
| 2025-12-24 | Amgen Inc. | MONROE BIOMEDICAL RESEARCH LLC | $20,348 | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Marid | 2025 |
| 2025-12-24 | Amgen Inc. | MONROE BIOMEDICAL RESEARCH LLC | $19,300 | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Marid | 2025 |
| 2025-12-23 | Genentech, Inc. | MONROE BIOMEDICAL RESEARCH LLC | $2,838 | A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC | 2025 |
| 2025-12-22 | Genentech, Inc. | MONROE BIOMEDICAL RESEARCH LLC | $1,000 | A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC | 2025 |
| 2025-12-22 | Genentech, Inc. | MONROE BIOMEDICAL RESEARCH LLC | $1,000 | A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC | 2025 |
| 2025-12-22 | Eli Lilly and Company | Monroe Biomedical Research | $10,000 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WI | 2025 |
| 2025-12-22 | Genentech, Inc. | MONROE BIOMEDICAL RESEARCH LLC | $1,500 | A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC | 2025 |
| 2025-12-20 | PFIZER INC. | Monroe Biomedical Research | $432 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-12-19 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $4,643 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-19 | Verona Pharma, Inc. | Monroe Biomedical Research | $1,000 | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | 2025 |
| 2025-12-19 | SANOFI PASTEUR INC. | Monroe Biomedical Research Monroe | $503 | A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety a | 2025 |
| 2025-12-19 | Verona Pharma, Inc. | Monroe Biomedical Research | $850 | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $472 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $472 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $472 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $1,352 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $1,352 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $1,352 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | PHARMASEEK LLC | $4,062 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-17 | Eli Lilly and Company | Monroe Biomedical Research | $915 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WI | 2025 |
| 2025-12-17 | Eli Lilly and Company | Monroe Biomedical Research | $934 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WI | 2025 |
| 2025-12-17 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $500 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-12 | Verona Pharma, Inc. | Monroe Biomedical Research | $328 | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | 2025 |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $100 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $1,000 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $6,729 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $500 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $500 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $500 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-10 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $800 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-05 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $1,000 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-01 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $3,417 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-01 | Alnylam Pharmaceuticals Inc. | Monroe Biomedical Research | $500 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-11-29 | PFIZER INC. | Monroe Biomedical Research | $1,000 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-11-25 | SANOFI PASTEUR INC. | Monroe Biomedical Research Monroe | $1,573 | A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety a | 2025 |
| 2025-11-24 | ModernaTX, Inc. | Monroe Biomedical Research | $8,524 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-11-24 | ModernaTX, Inc. | Monroe Biomedical Research | $5,882 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-11-24 | ModernaTX, Inc. | Monroe Biomedical Research | $17,532 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Monroe, NC, county Union County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Monroe, NC | County Union County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 36,759 | 250,958 | 10,730,404 |
| Population, 2020 census P1 | 34,562 | 238,267 | 10,439,388 |
| Median age B01002 | 35.5 | 39.2 | 39.1 |
| Under 18 B01001 | 24.5% | 25.6% | 21.8% |
| 65 and over B01001 | 14.9% | 13.5% | 17.2% |
| Households B11001 | 12,620 | 84,237 | 4,282,345 |
| Foreign born B05002 | 17.8% | 12.2% | 9.1% |
| Median household income B19013 | $72,540 | $102,900 | $72,388 |
| Median family income B19113 | $80,817 | $118,218 | $90,290 |
| Per capita income B19301 | $31,089 | $46,949 | $41,385 |
| Poverty rate B17001 | 13.3% | 7.7% | 13.0% |
| Unemployment rate B23025 | 4.6% | 4.2% | 4.7% |
| Civilian labor force B23025 | 18,613 | 132,592 | 5,336,863 |
| Mean commute (minutes) B08013 | 30.1 | 29.8 | 25.1 |
| Bachelor's degree or higher B15003 | 24.1% | 40.5% | 35.7% |
| Housing units B25001 | 13,469 | 88,851 | 4,895,668 |
| Owner-occupied B25003 | 61.6% | 81.6% | 66.6% |
| Renters B25003 | 38.4% | 18.4% | 33.4% |
| Median home value B25077 | $309,100 | $417,300 | $288,900 |
| Median gross rent B25064 | $1,246 | $1,496 | $1,228 |
| White, not Hispanic B03002 | 43.7% | 66.8% | 60.0% |
| Black B03002 | 19.7% | 10.9% | 20.0% |
| Hispanic or Latino B03002 | 30.9% | 13.4% | 11.3% |
| Asian B03002 | 1.0% | 4.5% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Monroe, NC.
Comments